Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions
NCT06658405Phase 2Recruiting
- Sponsor
- Centre Oscar Lambret
- Start
- Jan 2025
- Primary completion
- Oct 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Centre Oscar Lambret. Primary endpoint: Proportion of HPV-negative status at 2 years. Started Jan 2025; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06658405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06658405.